GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It

2Firsts Events by 2FIRSTS Charlotte, edited by Sophia Lv
May.30.2024
GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
The "GTNF InFocus 2024" was held online as scheduled on the evening of May 22, Beijing time. The forum focused on two core themes: "Myths about Nicotine and Its Harms" and "The Nicotine Industry from an Agricultural Perspective."

The "GTNF InFocus 2024" was held online as scheduled on the evening of May 22, Beijing time. The forum focused on two core themes: "Myths about Nicotine and Its Harms" and "The Nicotine Industry from an Agricultural Perspective."

 

The forum began with a welcome address from GTNF founder and Executive Director of the GTNF Trust Fund, Elise Rasmussen. In her speech, Rasmussen highlighted the uncertainty in global nicotine regulation, emphasizing the volatile tobacco policies in the UK and US since the end of last year. She also expressed gratitude to the experts sharing their insights at the forum.

 

Dispelling Nicotine Myths: A "Horror" Narrative Around E-Cigarettes

 

The first keynote speech was delivered by Michael Strupp, Professor of Neurology at Ludwig Maximilian University of Munich Medical School. His presentation focused on the pathological characteristics of nicotine and synthetic nicotine, detailing the molecular structure, receptors, and anatomical absorption process in the human body.

 

Professor Strupp reiterated his key point that nicotine, as a molecular structure, is not carcinogenic. He vividly compared e-cigarettes to traditional combustible cigarettes using the analogy of electric cars versus fuel cars, highlighting that the underlying logic of e-cigarettes is similar to the advantages of electric cars, which are "a cleaner process and less damage."

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
Michael Strupp, Professor of Neurology at Ludwig Maximilian University of Munich Medical School

 

Following Professor Strupp's speech, James Murphy, Director of Research and Science at British American Tobacco (BAT), delivered the second keynote speech. Murphy, who previously led BAT's Group of Reduced Risk Products (PRRP) Science and was the product manager for the Americas and Sub-Saharan Africa regions, drew from his experiences in developing markets to argue that the public health community needs to adopt a consistent scientific viewpoint on new-generation tobacco products to provide regulators worldwide with accurate information and create a "stable framework."

 

In his keynote, Murphy shared his experiences and stated that the dual themes of the forum have dual significance in "promoting public health" and "focusing on social welfare."

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
James Murphy, Director of Research and Science at British American Tobacco (BAT)

 

Deepening the Discussion on Nicotine and E-Cigarettes

 

The first panel discussion invited several industry experts to delve deeper into misunderstandings and myths about nicotine and e-cigarettes. The discussion was moderated by Jasjit Ahluwalia, Professor of Behavioral and Social Sciences and Professor of Medicine at Brown University School of Public Health and Alpert Medical School. The panelists included Delon Human, family doctor and president of the "Health Diplomats" group, Dave Dobbins, former COO of the American Legacy Foundation/Truth Initiative, and Sudhanshu Patwardhan, nicotine expert and health technology entrepreneur.

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
The first panel discussion deepened the discussion on misunderstandings and myths about nicotine and e-cigarettes

 

Ahluwalia noted that over the past decade, as the e-cigarette market has grown, the idea that "e-cigarettes are more harmful than traditional combustible cigarettes" has gained traction among smokers, leading many who had switched to e-cigarettes to return to smoking. He described this as "incredible"; the panelists agreed that the industry should invest more resources in related research to combat the "horror narrative" with science.

 

Dobbins, from a market perspective, discussed the proper direction for regulating nicotine products from the standpoint of human rights and legal principles. He argued that every adult's actions and choices are their own responsibility, and thus "adults need to be treated as adults, not managed with flavor bans or outright prohibitions on nicotine intake methods."

 

Nicotine from an Agricultural Perspective: Ensuring Farmers' Interests

 

The second panel discussion focused on the upstream tobacco farming and the welfare of related farmers, an area less frequently highlighted by the industry. The session included George Cassels-Smith, CEO of a tobacco technology company, Ramsey S. Lewis, Professor of Plant Breeding at North Carolina State University, Carlos Pulcinelli, Global Project Manager at Alliance One International, and Lea Scott, Senior Vice President of Universal Leaf Tobacco Co.

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
The second panel discussion focused on the upstream tobacco farming and the welfare of related farmers

 

During the discussion, the panelists analyzed the development of upstream tobacco farming from the perspectives of tobacco farmers, buyers, and regulators across the supply chain. They emphasized the critical importance of tobacco leaf quality for all stakeholders. Professor Lewis highlighted the success of developing high-quality, high-yield, disease-resistant tobacco varieties through genetic modification over the past decade. He suggested that future research and development to increase the added value of raw tobacco leaves would be a significant focus for the industry.

 

The panelists unanimously agreed that not everyone realizes that nicotine, like large-scale agriculture in livestock and crops, involves a "farm-to-table" process. Ensuring the interests of farmers who grow tobacco is essential to meet the increasing ESG (Environmental, Social, and Governance) requirements from regulators and society for nicotine companies.

 

 

About GTNF InFocus


 

InFocus is the largest online tobacco and nicotine conference. Bringing together thought leaders, industry voices, and leaf and public health experts。
 

2FIRSTS focused on the core topics and significant viewpoints of the forum, conducting in-depth interviews with government officials, business executives, and industry experts from various countries. We published over 20 high-quality reports in both text and video formats.

This series of reports not only promoted GTNF's global reach but also provided valuable information and profound insights for the high-quality development of the e-cigarette industry.

Here is an overview of key content covered by 2FIRSTS at GTNF 2023:

1. FDA CTP Director Brian King: Submitting PMTA is No Equivalent to Legal Sale
 https://www.2firsts.com/news/fda-director-brian-king-on-e-cigarette-compliance-and-tracking-systems

2. GTNF 2023: Sustainable Development and New Vape Products
https://www.2firsts.com/news/the-future-of-e-cigarettes-sustainable-development-and-new-products

3. GTNF Discusses Addressing Youth Misuse of Harm Reduction Products: A Collaborative Effort Needed
 https://www.2firsts.com/news/gtnf-discusses-addressing-youth-misuse-of-harm-reduction-products-a-collaborative-effort-needed

4. Interview with GTNF Founder: Transform Industry Through Unique Dialogues
https://www.2firsts.com/news/interview-with-gtnf-founder-transform-industry-through-unique-dialogues

Moving forward, 2FIRSTS will continue to closely track the latest developments and trends in the e-cigarette industry, committed to providing readers with cutting-edge information and in-depth analysis. This ensures that readers receive accurate and comprehensive first-hand industry updates promptly.

 

IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
China exported $979 million of vape-related products in August 2026, up 3.3% from a year earlier but down 6.4% from July. The UK replaced the U.S. as the main source of growth: UK-bound shipments jumped 51.4% to a 2026 high of $177 million, while exports to the U.S. fell 12.4% to $339 million. Shipments to markets outside the U.S. increased 14.2%, broadening growth beyond the market that had driven July’s rebound.
News
Sep.23 by 2Firsts Perspectives
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
China’s Vape-Related Exports Rose 4.5% in Q3 2026 as 21.6% Growth in Shipments to the UK Offset a Decline in Shipments to the US
China’s Vape-Related Exports Rose 4.5% in Q3 2026 as 21.6% Growth in Shipments to the UK Offset a Decline in Shipments to the US
China's vape-related exports rose 4.5% year over year to $2.86 billion in the third quarter of 2026, led by stronger shipments to the United Kingdom as exports to the United States declined. UK-bound shipments increased 21.6%, adding $81.9 million, while US exports fell 5.2%, or $53.6 million. Growth weakened through the quarter, with September exports down 6.3% globally and 37.8% to the US. Nicotine-containing vape products accounted for more than 82% of the quarterly net increase, while device exports were nearly flat. Nine-month exports totaled $7.82 billion, up 4.0%.
DATA
Oct.26
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08